Taurocholate induces biliary differentiation of liver progenitor cells causing hepatic stellate cell chemotaxis in the Ductular Reaction: Role in pediatric cystic fibrosis liver disease


Published in:
The American journal of pathology

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© 2017 Elsevier Ltd.
This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/, which permits distribution and reproduction for noncommercial purposes, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and/or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Download date: 30. Apr. 2021
Taurocholate induces biliary differentiation of liver progenitor cells causing hepatic stellate cell chemotaxis in the Ductular Reaction: Role in pediatric cystic fibrosis liver disease.

Katarzyna N. Pozniak, Michael A. Pearen, Tamara N. Pereira, Cynthia SM. Kramer, Priyakshi Kalita-De Croft, Sujeevi K. Nawaratna, Manuel A. Fernandez-Rojo, Geoffrey N. Gobert, Janina EE. Tirnitz-Parker, John K. Olynyk, Ross W. Shepherd, Peter J. Lewindon, Grant A. Ramm

PII: S0002-9440(17)30375-9
DOI: 10.1016/j.ajpath.2017.08.024
Reference: AJPA 2732

To appear in: The American Journal of Pathology

Received Date: 6 April 2017
Revised Date: 14 July 2017
Accepted Date: 11 August 2017


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Taurocholate induces biliary differentiation of liver progenitor cells

causing hepatic stellate cell chemotaxis in the Ductular Reaction:

Role in pediatric cystic fibrosis liver disease.

Short title: Taurocholate regulates fibrosis in CF liver disease

Katarzyna N Pozniak1,2*, Michael A Pearen1*, Tamara N Pereira1*, Cynthia SM Kramer1, Priyakshi Kalita-De Croft1, Sujeevi K Nawaratna3, Manuel A Fernandez-Rojo1,2, Geoffrey N Gobert3,4, Janina EE Tirnitz-Parker5,6, John K Olynky5,7,8, Ross W Shepherd1, Peter J Lewindon1,2,9, and Grant A Ramm1,2

* These authors contributed equally

Affiliations:

1 Hepatic Fibrosis Group and 3 Molecular Parasitology Group, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia

2 Faculty of Medicine, The University of Queensland, Brisbane QLD, Australia

4 School of Biological Sciences, Queen’s University Belfast, UK

5 School of Biomedical Sciences, CHIRI Biosciences, Curtin University, Bentley WA, Australia

6 School of Medicine and Pharmacology, University of Western Australia, Fremantle WA, Australia

7 Department of Gastroenterology & Hepatology, Fiona Stanley and Fremantle Hospitals, Perth, WA, Australia

8 Faculty of Health Sciences, Edith Cowan University, Perth, WA, Australia
Department of Gastroenterology, The University of Queensland, Brisbane, QLD, Australia

**Corresponding author:**

Prof Grant A. Ramm  
Head, Hepatic Fibrosis Group  
QIMR Berghofer Medical Research Institute  
PO Royal Brisbane and Women's Hospital  
Brisbane, Queensland, 4029  
Phone: 61-7-33620177  
Fax: 61-7-33620191  
Email: Grant.Ramm@qimrberghofer.edu.au

**Disclosures:** The authors have no conflicts of interest and nothing to disclose.

**Grant support:** This work was supported by a research grant from the National Health and Medical Research Council (NHMRC) of Australia (Grant No. APP1048740 to GAR, PJL, RWS). Professor Grant A. Ramm is supported by a Senior Research Fellowship from the NHMRC of Australia (Grant No. APP1061332). John K. Olynyk is a recipient of a Practitioner Fellowship from the NHMRC of Australia (Grant No. APP1042370).

**Number of text pages:** 36  
**Number of figures:** 14 + 2 Supplementary figures  
**Number of Tables:** 1  
**Electronic word count:** 3704 (excluding methods, tables/figures, references)  
**Abstract word count:** 220
ABSTRACT

Cystic fibrosis liver disease (CFLD) in children causes progressive fibrosis leading to biliary cirrhosis, however its cause(s) and early pathogenesis are unclear. We hypothesised that a bile acid-induced Ductular Reaction (DR) drives fibrogenesis. We evaluated the DR by cytokeratin-7 immunohistochemistry in liver biopsies, staged for fibrosis, from 60 children with CFLD and demonstrated that the DR was significantly correlated with hepatic fibrosis stage and biliary taurocholate levels. To examine the mechanisms involved in DR induction liver progenitor cells (LPCs) were treated with taurocholate and key events in DR evolution were assessed: LPC proliferation, LPC biliary differentiation and hepatic stellate cell (HSC) chemotaxis. Taurocholate induced a time-dependent increase in LPC proliferation and expression of genes associated with cholangiocyte differentiation (cytokeratin-19, connexin-43, integrin-β4 and γ-glutamyltranspeptidase [GGT]), while the hepatocyte specification marker HNF4α was suppressed. Functional cholangiocyte differentiation was demonstrated via increased acetylated α-tubulin and SOX9 proteins, the number of primary cilia+ LPCs and increased active GGT enzyme secretion. Taurocholate induced LPCs to release MCP-1, MIP1α and RANTES into conditioned medium causing HSC chemotaxis, which was inhibited by anti-MIP1α. Immunofluorescence confirmed chemokine expression localized to CK7+ DR and LPCs in CFLD liver biopsies. This study suggests that taurocholate is involved in initiating functional LPC biliary differentiation and the development of the DR, with subsequent induction of chemokines that drive HSC recruitment in CFLD.
INTRODUCTION

Cystic fibrosis-associated liver disease (CFLD) is characterized by indolent intrahepatic cholestasis that usually manifests by early adolescence \(^1\). Cystic fibrosis (CF) is caused by a defect in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) which, among other functions, maintains the flow of bile in contact with cholangiocytes by facilitating the movement of water and bicarbonate ions into bile. Abnormal ion/water transport leads to inspissated bile and cholestasis with focal fibrosing destruction of intrahepatic bile ducts \(^2\). The resulting pattern of injury is focal biliary cirrhosis for which there is no known treatment and which may progress to cause portal hypertension, multilobular biliary cirrhosis and liver failure. However, only 10% of children with CF will develop portal hypertension and cirrhosis, a higher prevalence than the overall CF population, indicating a strong survival disadvantage. The cause and mechanism of this variable presentation and severity of pathology are not known \(^3\).

The Ductular Reaction (DR) is characterized by the expansion of a population of bipotential liver progenitor cells (LPCs) which can differentiate towards the cholangiocyte lineage into reactive bile ductules, as well as intermediate hepatocytes \(^4,5\). LPCs have been proposed by some groups to reside within peri-portal areas associated with the Canals of Hering \(^6\), although their precise cellular origin is the subject of ongoing controversy \(^7\). LPC expansion is thought to mediate a secondary pathway of liver regeneration, which occurs when the process of hepatocyte replication is overwhelmed in chronic liver disease \(^8\). In cholestasis this expansion is postulated to be a futile attempt to drain excess bile via the formation of additional bile ductules and to replace damaged hepatocytes \(^9\). The DR is observed along with activation of hepatic stellate cells (HSCs) and an increase in hepatic fibrosis, which is seen in
adult liver diseases that show periportal damage in cholestatic liver diseases \(^5,^6\), as well as other conditions such as viral hepatitis A \(^1^1\) and C \(^1^2\), \textit{HFE}-associated hemochromatosis \(^1^3\), alcoholic and non-alcoholic fatty liver diseases \(^1^4\) and post-transplant HCV \(^1^5\). This has led to the hypothesis that the two processes of LPC expansion and HSC activation with the resultant DR and fibrosis, respectively, are closely related. While histological evidence of a DR has previously been demonstrated in children with extrahepatic biliary atresia \(^1^6,^1^7\), the potential role of LPCs driving HSC activation and fibrosis via development of the DR has not previously been assessed in CFLD.

Bile acids are synthesized in hepatocytes from cholesterol and are usually conjugated to taurine or glycine to form bile salts and secreted into the bile canaliculi. These bile secretions flow into bile ducts, where they are stabilized by bicarbonate ions and water secreted by cholangiocytes as they are excreted from the liver into the gall bladder. They aid lipid digestion in the duodenum by forming micelles. However, their partial hydrophobic nature, which is essential in forming micelles, also makes them toxic to the liver in higher concentrations \(^1^8\). The bile salt composition within bile is altered in children with CFLD, as we have previously shown \(^1^9\), and is comparable to that of mice following bile duct ligation \(^2^0\). In particular, the hydrophobic bile salt, taurocholate is significantly increased in both bile and serum of children with CFLD \(^2^1\). Taurocholate and other bile salts are able to upregulate the expression of inflammatory genes in the liver \(^2^2\). Taurocholate has also been shown to stimulate cytokine secretion from cholangiocytes \(^2^3\) and hepatocytes \(^2^1\), which induce transdifferentiation of portal fibroblasts \(^2^4\) as well as facilitating HSC migration \(^2^1,^2^5\). We previously demonstrated that taurocholate induced the expression of monocyte chemotaxis protein-1 (MCP-1) in normal hepatocytes, and that MCP-1 produced by cholestatic hepatocytes from bile duct-ligated rats induced the chemotaxis of HSCs \(^2^1\). Markedly
increased expression of MCP-1 was observed in hepatocytes and cholangiocytes in the liver of children with cholestatic liver diseases \(^{21}\).

In this study we investigated whether the DR is present in the liver of children with CFLD and examined mechanisms associated with its induction and role in fibrogenesis. We compared the severity of the DR in CFLD liver biopsies with those from other, more aggressively cholestatic pediatric liver disease and then specifically examined a potential mechanism of DR induction in CFLD through investigating the relationship between biliary taurocholate concentrations and the DR in liver biopsies from children with CFLD \textit{in vivo}. We then used \textit{in vitro} cell culture models and \textit{ex vivo} liver slices to investigate the \textit{in vivo} observed effects of elevated taurocholate on LPC differentiation, the secretion of chemokines by LPCs and their chemotactic effects on HSCs in driving hepatic fibrogenesis.

**MATERIALS AND METHODS**

**Patient specimens.** This study is part of a long-term prospective cohort study of patients with CFLD identified and referred from the CF Clinic, Royal Children’s Hospital, Brisbane, previously well documented \(^{19, 21, 26-28}\). CFLD was defined as two of the following: (i) hepatomegaly ± splenomegaly; (ii) persistent (>6mo) elevation of serum alanine aminotransferase (>1.5x upper limit normal); and (iii) abnormal liver ultrasound (abnormal echogenicity or nodular edge). Those with liver synthetic dysfunction or a history of hepatobiliary surgery were excluded. The study conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Ethics Committees of the Royal
Children’s Hospital, Brisbane and the QIMR Berghofer Medical Research Institute. Informed consent was obtained from parents or patients.

Liver tissue was available from 60 children with CFLD (age, 11.8±4.5yrs). For comparison with other pediatric cholestatic liver diseases, liver tissue was also available from three infants with biliary atresia (BA: age, 1.2±1.4yrs), five with idiopathic neonatal hepatitis (NH: age, 3.4±3.6yrs), as well as four pediatric donor liver controls (age, 6.8±4.5yrs). Bile was available from 7 children with CFLD.

**Immunohistochemistry.** Formalin-fixed, paraffin-embedded liver sections were subjected to heat antigen retrieval, before exposure to 3% hydrogen peroxide in PBS and Background Sniper (Biocare Medical). Sections were then stained with primary antibody: mouse anti-human CK7 mAb (1:100; DAKO), secondary antibody: rabbit anti-mouse biotinylated IgG (1:400, DAKO), with detection using a streptavidin-biotin/horseradish peroxidase kit (DAKO) and chromogenic substrate 3,3′-diaminobenzidine tetrahydrochloride (Sigma-Aldrich), and counterstained with hematoxylin. Digital images were captured using Aperio ScanScope XT slide scanner (Aperio Technologies) under 20x magnification at 0.5µm/pixel. Image analysis was performed using Aperio Positive Pixel Count algorithm v9.1. Positively stained cells were counted, normalized to the total section area and results correlated with Scheuer’s hepatic fibrosis staging.

**Biliary taurocholate measurement.** Taurocholate concentration was measured in endoscopic bile samples available from seven patients with CFLD, as previously described \(^2\)\(^1\). Liver biopsies were processed for histochemical CK7 quantification as above. All patients had histological evidence of hepatic fibrosis. Biliary taurocholate levels were correlated with CK7 quantification.
Culture of cell lines and *in vitro* studies. The murine LPC line PIL-2\(^29\) was cultured in Williams’ E medium containing 2mM glutamine, penicillin (100 U/ml), streptomycin (100 µg/ml), insulin (10 µg/ml), epidermal growth factor (10 ng/ml), insulin-like growth factor II (30 ng/ml) and 10% fetal bovine serum (FBS). The human HSC line LX-2 was cultured in DMEM with 2mM glutamine, penicillin (100 U/ml), streptomycin (100 µg/ml) and 2% FBS. PIL-2 cells were treated with taurocholate at 0-300µM concentration to establish a dose-response, with an optimal concentration of 150µM taurocholate chosen for all *in vitro* and *ex vivo* experiments, as previously described\(^21\). For differentiation assays, cells were lysed 1-4 days after taurocholate treatment. LPC differentiation was assessed using RT-qPCR and/or western blot analysis evaluating markers for cholangiocyte (connexin 43, *Cx43*; cytokeratin 19, *Ck19*; integrin beta 4, *Itgb4*; γ-glutamyl transpeptidase, *Ggt*; epithelial cell adhesion molecule, *EpCam*; SYR-related HMG box transcription factor 9, *Sox9*) and hepatocyte (albumin; hepatocyte nuclear factor 4α, *Hnf4α*) phenotype.

RT-qPCR for LPC differentiation marker and chemokine mRNA expression. RNA was extracted from both untreated and taurocholate-treated PIL-2 cells using the RNeasy kit (Qiagen) and 1µg was reverse-transcribed into cDNA using SensiFast (Bioline). Real-time qPCR was performed on a Biorad CFX96 with HPRT used as the reference gene. Primers are listed in Table 1.

MTT cell proliferation assay. Cell proliferation was measured over a two hour period at 1-4 days following treatment of PIL-2 cells with 150µM sodium taurocholate using the method of Alley *et al.*\(^30\). Absorbance was measured at 570nm with a 620nm reference filter.
Western blot analysis.

Cell lysates were prepared from PIL-2 cells disrupted in RIPA buffer with Complete EDTA-free protease inhibitors (Roche). Lysates were resolved on 10% SDS-PAGE gels as described in Laemmli et al.\textsuperscript{31} and transferred to polyvinyl difluoride membranes (Immobilon-FL; Millipore). Membranes were probed with anti-CK19 (Abcam ab15463; 1:2000); anti-SOX9 (Merck Millipore #AB5535; 1:1000); anti-HNF4\textalpha (Santa Cruz sc6556; 1:1000); anti-acetylated \(\alpha\)-tubulin (Sigma-Aldrich T7451; 1:1000); with anti-\(\beta\)-actin used to detect the \(\beta\)-actin loading control (Cell Signaling; 1:2000), in TBST LI-COR Odyssey blocking buffer. Blots were probed with an anti-mouse 680RD or anti-rabbit 800CW secondary at 1:20000 in TBST LI-COR Odyssey blocking buffer. Secondary localization was detected with the LI-COR Odyssey CLx Infrared Imaging System. Band quantification was performed using Image Studio Lite version 5.2.

Immunofluorescence. To examine primary cilia, PIL-2 cells were grown on glass coverslips to 60-80% confluence and treated for three days ± 150\(\mu\)M taurocholate and serum-starved overnight prior to fixation. Cells were placed at 4°C for 30 minutes to destabilize microtubules and then fixed in 4% paraformaldehyde for 10 minutes. Cells were permeabilized with 0.5% Triton X-100, blocked with 5% BSA and probed with mouse anti-acetylated \(\alpha\)-tubulin (Sigma-Aldrich; 1:600) and rabbit anti-\(\gamma\)-tubulin (Sigma-Aldrich; 1:400) antibodies overnight in PBST with 1% BSA. Primary binding was probed with AlexaFluor 594 donkey anti-rabbit (Invitrogen) and AlexaFluor 594 goat anti-mouse (Invitrogen) at 1:500 for 1hr in PBST with 1% BSA. Images were captured with a Zeiss AxioScop2. Quantification of acetylated \(\alpha\)-tubulin spots was performed using Particle Analysis in ImageJ (NIH).
To identify the cellular source of HSC chemokines in liver biopsies from children with CFLD, we performed dual immunofluorescence for chemokines MCP-1; regulated upon activation, normal T cell expressed and secreted (RANTES); or macrophage inflammatory protein 1α (MIP1α), together with the LPC/DR marker, CK7. Primary antibodies used were: mouse anti-CK7 mAb (1:150, Abcam), goat anti-human MCP-1 pAb (1:8, R&D Systems), goat anti-human CCL5/RANTES pAb (1:83, R&D Systems), goat anti-human MIP1α (1:50, R&D Systems), incubated overnight at 4°C followed by a 30 min incubation step at room temperature with donkey anti-mouse IgG AlexaFluor 555 (1:300, Invitrogen) and donkey anti-goat IgG AlexaFluor 488 (1:300, Molecular Probes). Sections were mounted in Prolong Gold (Invitrogen) with DAPI and examined by confocal microscopy (Zeiss 780NLO).

**Ex vivo liver slice studies.** Precision-cut liver slices were performed as previously described. A minimum of three liver slices each from three separate C57BL6 WT mice for each time point and each treatment group, were incubated in Williams’ E medium containing 2mM glutamine, penicillin (100 U/ml), streptomycin (100 µg/ml) and 10% FBS at 37°C for two and four days ± 150µM taurocholate. Conditioned medium was examined for GGT enzyme activity. Slices were harvested for mRNA quantitation using RT-qPCR.

**γ-Glutamyl Transpeptidase Activity Assay.** GGT activity was determined from *in vitro* cell cultures and *ex vivo* liver slice conditioned media using the GGT activity colorimetric assay kit (Sigma-Aldrich). Protein for normalization was measured using the Pierce BCA protein assay (Thermo Fisher Scientific).

**Quantification of cytokine protein secretion from LPCs ± taurocholate.** Chemokines MCP-1, MIP1α and RANTES, released from LPCs, were quantified using the Cytokine Bead
Array (CBD; BD Biosciences), according per manufacturer’s protocol. The concentrations of transforming growth factor-1β (TGF-β1) and platelet-derived growth factor–BB (PDGFB) secreted by LPCs were determined by ELISA (R&D Systems).

Chemotaxis assays. Induction of HSC chemotaxis via taurocholate treatment of LPCs was examined by measuring cell migration through 8µm 24-well cell culture inserts (Greiner Bio-One) in modified Boyden chambers. Assays were performed using 0.5x10⁶ LX-2 cells (serum starved overnight) per ml within the insert and the inserts were placed suspended within test medium. Test medium was either normal non-conditioned serum-free Williams’ E medium or conditioned medium from LPCs ± taurocholate. Chemokine neutralization was performed by pre-treating conditioned medium with 2.5 µg/ml anti-mouse MCP-1 (AF-479-NA), 1 µg/ml anti-mouse MIP1α (AF-450-NA) or 1 µg/ml anti-mouse RANTES (AF478) polyclonal neutralization antibodies (R&D Systems), 1hr prior to the assay. Testing of MIP1α as chemokine used murine (R&D Systems; 40-337) or human (R&D Systems; 40-364) recombinant purified MIP1α proteins. Blocking of the CCR5 receptor used the neutralization/blocking antibody MAB182 (R&D Systems) applied to the LX-2 cells within the Boyden chamber insert for 1 h prior to the assay at an insert concentration of 20 µg/ml. Chemotaxis assay were performed for 24h and migrated cells on the underside of the insert membrane were stained with Cell Stain (Part No. 90144; Merck-Millipore), treated with Extraction Buffer (Part No. 90145; Merck-Millipore) and absorbance measured at 560nm. Results from separate experimental replicates were normalized to the mean absorbance of control samples (non-conditioned serum-free assay medium and FBS positive control).

Statistical analysis. Results are presented as mean ± SEM. Statistical analysis was performed with GraphPad Prism 6 (GraphPad Software Inc.). For immunohistochemical analysis: Mann-
Whitney test and one-way non-parametric ANOVA analysis with Kruskal-Wallis and Dunn’s multiple comparison test. For chemotaxis assay: One-way ANOVA with Sidak’s multiple comparison. For qPCR time course: ANOVA with Sidak’s post-hoc test and two-way ANOVA to examine the overall treatment effect. For qPCR chemokine expression: unpaired t-test. For CBA assay: unpaired t-test with Welch’s correction. Differences were considered significant when p<0.05.

RESULTS

Ductular Reaction correlates with fibrosis and biliary taurocholate in CFLD. The DR, as assessed by CK7 expression, was markedly increased in CFLD and contained expanded reactive bile ducts, and both single LPCs and strings of biliary cells/LPCs (Figure 1). The DR was mainly present in the periphery of portal tracts as irregular strands/chords of CK7+ cells and as isolated single CK7+ LPCs in adjacent areas. This DR was increased in CFLD (p<0.05), as well as in BA (p=0.114) and NH (p=0.016) versus controls (Figure 2A). When stratified for fibrosis stage, there was a highly significant positive correlation between CK7 staining and increasing fibrosis stage in CFLD (Spearman r = 0.59, p < 0.0001) (Figure 2B). Bile samples were available from 7 of the 60 children with CFLD. There was a positive statistical correlation between biliary taurocholate concentrations and the extent of the DR as assessed via CK7 quantification (r = 0.528; p = 0.0321) (Figure 2C).

Taurocholate induces biliary differentiation of LPCs. As we demonstrated that in CFLD the extent of the DR correlates with both fibrosis severity and biliary taurocholate levels, we hypothesized that taurocholate may induce LPC biliary differentiation and the DR. To interrogate this hypothesis, we treated the murine LPC line PIL-2 with 0-300 µM
taurocholate for four days to establish the optimal conditions for all *in vitro* and *ex vivo* studies. Taurocholate induced a dose-dependent increase in mRNA expression of the cholangiocyte markers *Cx43* (Figure 3A; ANOVA, p<0.0001) and *Ck19* (Figure 3B; ANOVA, p<0.0001). A taurocholate concentration of 150µM was chosen for all subsequent experiments as has previously been described in *in vitro* studies \(^{21, 23}\), and also being consistent with previous observations in children with CFLD that displayed a mean biliary taurocholate concentration of 108µM vs 41µM in healthy controls \(^{21}\).

PIL-2 cells were treated with 150µM taurocholate for 0-4 days and markers of cholangiocyte differentiation were further assessed. Taurocholate induced a time-dependent increase in mRNA expression of cholangiocyte markers *Cx43* (Figure 3C; ANOVA p<0.0001), *Ck19* (Figure 3D; ANOVA p<0.0001), *Itgb4* (Figure 3E; ANOVA p<0.029), and *Ggt* (Figure 3F; ANOVA p<0.001). Taurocholate treatment did not significantly alter expression of two other cholangiocyte markers, *EpCam* and *Sox9* (data not shown).

Of interest, we observed a concomitant decrease in mRNA expression of the master regulator of hepatic differentiation, *Hnf4α* (Figure 4A; ANOVA p=0.0255). A second hepatocyte marker, *albumin (Alb)* showed no significant difference with taurocholate treatment (Figure 4B). Taken together, these results suggest that taurocholate augments the cholangiocyctic differentiation of the LPC line PIL-2.

**LPC proliferation is induced by taurocholate.** Integral to the formation of the DR is the expansion of LPCs in chronic liver disease. To assess the potential effect of taurocholate on LPC proliferation, PIL-2 cells ± 150µM taurocholate were subjected to an MTT cell proliferation assay every 24 hrs for 1-4 days. Taurocholate induced a time-dependent increase
in LPC proliferation (Figure 5; ANOVA, p=0.0003), which was most notable early, i.e., after 1-2 days.

**Taurocholate induces differentiation of LPCs into functional cholangiocytes** While Figure 3 demonstrates that taurocholate induced the expression of cholangiocyte-associated genes in LPCs, an assessment of actual cholangiocyte function remained to be confirmed. Thus, we examined expression of proteins involved in various aspects of biliary cell function. We observed that CK19, a protein responsible for the structural integrity of cholangiocytes is significantly induced by taurocholate (Figure 6A and B; p=0.0006). Taurocholate also induced a significant >2.5-fold increase in SOX9 protein, a key transcriptional regulator of cholangiocyte differentiation and bile duct formation (Figures 6A and C; p=0.001). Conversely, HNF4α protein expression, a marker and transcriptional regulator of hepatocyte specification, was significantly decreased by taurocholate (Figures 6A and D; p=0.019).

One key morphological characteristic of cholangiocytes is the presence of primary cilia with acetylated α-tubulin being a key structural component. Western blot analysis revealed a significant induction of acetylated α-tubulin protein expression in taurocholate-treated LPCs (Figures 6A and E; p=0.026). As acetylated α-tubulin can also be found within other cellular structures such as microtubule networks, we further investigated the cellular localization of acetylated α-tubulin using immunofluorescence of LPCs ± taurocholate. Expression of acetylated α-tubulin causes primary cilia to appear as discrete dots or lines, while microtubule networks form thin filament-meshed patterns. As can be seen in Figure 7A, taurocholate induced a marked increase in the number of acetylated α-tubulin+ primary cilia when compared to controls, with quantitation of the relative fluorescence showing a 2.4-fold increase (p=0.022) (Figure 7B).
Another measure of functional LPC-cholangiocyte differentiation is the production of enzymatically active GGT, which is expressed and released by cholangiocytes within bile ducts. PIL-2 cells were treated ± 150µM taurocholate for 1-4 days with conditioned medium removed for analysis every 24hrs. Taurocholate induced a significant time-dependent increase in GGT activity (ANOVA, p<0.0001), with maximal production between days 3-4 (Figure 7C). At the conclusion of the experiment (day 4), this result remained highly significant when corrected for cellular protein concentration (Supplementary Figure S1).

**The effect of taurocholate in ex vivo precision-cut liver slices.** To demonstrate potential physiological relevance of our in vitro observation, we used precision-cut liver slices from normal control mice, treated ± 150µM taurocholate for up to four days. The hepatic mRNA expression of Cx43, as a representative cholangiocyte marker, was significantly increased in a time-dependent manner (Figure 8A; ANOVA, p=0.0354). Conditioned medium collected was assayed for GGT activity and normalized to liver slice wet weight. Taurocholate again induced a significant increase in GGT activity, peaking at day 2 (Figure 8B; ANOVA, p=0.0021).

**Chemokine expression induced by taurocholate in LPCs.** PIL-2 cells treated with 150µM taurocholate showed significantly increased expression of MCP-1, MIP1α, and RANTES mRNA at 6hrs (Figure 9A). We also examined the gene expression of the profibrotic cytokine TGF-β1 and HSC mitogen PDGFB, which both have HSC chemotactic potential. While taurocholate induced increased expression of both TGF-β1 and PDGFB, this did not reach statistical significance (Figure 9A).
Conditioned medium from PIL-2 cells ± 150µM taurocholate for 6hrs or 24hrs was assessed for protein secretion of key hepatic chemokines. *Rantes*, *Mcp-1*, *Mip1α*, *Tgf-β1* and *Pdgfb* were all expressed constitutively by PIL-2 cells. After 6hrs taurocholate treatment resulted in a 2-fold increase in MIP1α protein release (*p*<0.0001), whereas RANTES and PDGFB increased by approximately 1.5-fold (Figure 9B). Taurocholate induced an increase in MCP-1 secretion, however this did not reach statistical significance. By 24hrs, chemokine levels were indistinguishable from controls, except for PDGFB, which remained elevated in response to taurocholate (*p*<0.05). No effect was observed on TGF-β1 release.

**HSCs migrate in response to chemokines secreted by taurocholate-treated LPCs.** Chemotaxis of the LX-2 HSC line was significantly induced by conditioned medium from PIL-2 cells treated with taurocholate for either 6hrs (*p*<0.001) or 24hrs (*p*<0.01) (Figure 10A). Similar levels of chemotaxis were demonstrated using primary rat HSCs (data not shown). To determine the identity of chemokines responsible for this chemotaxis, conditioned medium was pre-treated with neutralizing antibodies to various different chemokines. Chemotaxis was completely inhibited by anti-MIP1α neutralizing antibody (nAb), however, anti-RANTES nAb had no effect (Figure 10B). While chemotaxis of LX-2 cells was partially suppressed using anti-MCP-1 nAb, this did not reach statistical significance.

**HSCs migrate in response to MIP1α mediated by CCR5.** As shown in Fig 10B, chemotaxis of HSCs in response to conditioned medium from PIL-2 cells treated with taurocholate was inhibited by anti-MIP1α nAb. To strengthen the case for the involvement of MIP1α as a HSC chemotactic agent, a chemotaxis assay was performed on LX2 cells using either murine or human recombinant purified MIP1α. Both murine (Figure 11A; ANOVA,
p=0.022) and human (Figure 11B; ANOVA, p=0.0009) MIP1α produced a significant dose-dependent increase in HSC migration approaching the effect observed with the positive control (FBS).

LX-2 cells were examined for the expression of both known major hepatic MIP1α receptors, C-C chemokine receptor type 1 and 5 (CCR1 and CCR5). Using quantitative RT-PCR, expression of both Ccr1 and Ccr5 was demonstrated, with Ccr5 showing higher mRNA levels vs. Ccr1 (Supplementary Figure S2). To investigate if CCR5 was the major contributing receptor in HSC chemotaxis, LX-2 cells were pre-treated with an anti-CCR5 nAb. This antibody effectively attenuated the migration of LX-2 HSCs in response to both recombinant murine MIP1α (Figure 11C) and conditioned medium from PIL-2 cells treated with 150µM taurocholate (Figure 11D).

**DR cells and LPCs express chemokines in liver from children with CFLD.** To assess the potential clinical relevance of taurocholate-induced chemokine expression demonstrated in in vitro and ex vivo studies, liver sections from patients with CFLD (n=22) were examined for the cellular source of chemokines. Dual immunofluorescence confirmed that CK7+ DR cells, and single CK7+ LPCs, express MCP-1 (Figure 12A), RANTES (Figure 12B) and MIP1α (Figure 13A and B).

**DISCUSSION**

The DR is proposed to be associated with the initiation of hepatic fibrosis in a number of chronic liver diseases 4, 12, 34, 35. However, the precise mechanisms involved in its induction and indeed in the interactions between LPCs and HSCs, which may drive both the DR and fibrogenesis, remain to be elucidated. This histological process has been reported in many
adult liver diseases including chronic hepatitis C \(^{12}\), alcoholic and non-alcoholic steatohepatitis \(^{14, 35}\) and genetic hemochromatosis \(^{13}\). In these diseases, the DR correlates closely with severity of fibrosis and inflammation \(^{34}\). However, the presence or role of the DR has not previously been investigated in children with CFLD. Here we show that the DR is indeed present in CFLD (and comparable to the DR present in more aggressive pediatric fibrosing cholestatic diseases such as biliary atresia \(^{36, 37}\)) and the extent of the DR significantly correlates with fibrosis staging in CFLD, suggesting that mechanisms regulating these two processes are interrelated.

Extensive investigation into the individual mechanisms of LPC and HSC activation \(^{38}\) have elucidated a role for many different soluble mediators in hepatic fibrosis. Understanding the interaction between LPCs and HSCs is of great importance for clarifying the contribution of these cells in mediating fibrogenesis and for designing therapeutic strategies aimed at reduction of hepatic fibrosis.

Bile salt retention is part of the proposed mechanism of injury and biliary fibrosis in CFLD and we previously demonstrated that biliaryserum levels of the conjugated bile acid taurocholate are elevated in children with CFLD \(^{21}\). In the present study we demonstrated that the extent of the DR correlates with biliary taurocholate concentration in children with CFLD and thus speculate a potential mechanistic link. To determine whether taurocholate plays a role in inducing the DR, we used both an LPC \textit{in vitro} cell culture model and \textit{ex vivo} precision-cut liver slices, and employed a reductionist strategy to examine the impact of taurocholate on three key events in the evolution of the DR: LPC proliferation, biliary differentiation of LPCs and HSC chemotaxis.
In this study, we demonstrated that taurocholate increased LPC proliferation \textit{in vitro}, suggesting that taurocholate may play a role in enhancing LPC expansion as part of the DR in CFLD. This observation is supported by studies from Clouzeau-Girard et al. 39 showing that taurocholate leads to uncharacterized cell proliferation around the portal tracts in \textit{ex vivo} liver slices. Our data are also consistent with the observation that feeding taurocholate to rats increases cholangiocyte numbers 40, although this study did not distinguish whether these were mature adult cholangiocytes or derived from LPCs.

The biliary differentiation of LPCs and subsequent formation of reactive bile ductular structures appear to be an important component of DR development. We demonstrated a significant increase in expression of the cholangiocyte genes \textit{Ck19, Cx43, Itgb4} and \textit{Ggt1} in response to taurocholate treatment of LPCs. Conversely, the hepatocyte lineage marker \textit{Hnf4α} was decreased, with albumin expression unchanged. This \textit{in vitro} result may be consistent with LPC differentiation that occurs during the DR \textit{in vivo} and provides one potential mechanism for induction of the DR in pediatric cholestatic liver diseases such as CFLD. Further supporting this concept, we demonstrated that taurocholate induced functional cholangiocyte differentiation, evidenced through the increased expression of acetylated $\alpha$-tubulin, CK19 and SOX9 protein, increased numbers of LPCs elaborating primary cilia, as well as the secretion of enzymatically active GGT \textit{in vitro}. The effect of taurocholate on cholangiocyte function was further confirmed in \textit{ex vivo} precision-cut liver slices, showing induced expression of \textit{Cx43} mRNA and secretion of active GGT.

In addition, this study has demonstrated that taurocholate-exposed LPCs secrete a number of chemokines including MCP-1, MIP1$\alpha$, RANTES and PDGFB, however HSC chemotaxis in response to taurocholate-treated LPC conditioned medium appears principally due to MIP1$\alpha$. 
Neutralizing antibodies to either MIP1α in LPC conditioned medium or the MIP1α receptor CCR5 on HSCs attenuated TCA-treated LPC-induced HSC chemotaxis. Thus, we propose that MIP1α derived from bile acid-exposed LPCs, may recruit HSCs (via CCR5) during the DR and aid in the initiation of hepatic fibrosis in CFLD. We did not demonstrate that RANTES aided in the chemoattraction of HSCs. Neutralization of MCP-1 resulted in a limited inhibition of HSC chemotaxis, however this did not reach statistical significance due to biological variability of the data. RANTES and MCP-1 may induce recruitment of other cells to the LPC niche as part of the fibrogenic process such as additional LPCs or inflammatory cells, as we previously described21,41. Migration of HSC towards LPCs as well as HSC activation could explain why fibrosis begins in periportal regions of the liver, where there is decreased bile flow through bile ducts, and thus increased accumulation of hydrophobic bile acids19. This pattern of chemokine expression upon in vitro taurocholate treatment may be indicative of the specific role of LPCs in generating a microenvironment that aids in the activation of HSC. In the current study, immunofluorescence revealed that MCP-1, RANTES and MIP1α are all expressed by DR cells and CK7+ LPCs in liver from children with CFLD, providing in vivo evidence validating our in vitro observations.

HSC activation is also influenced by other cell types present during chronic liver injury and inflammation, as the LPC niche harbours immune cells including liver macrophages, which also secrete MCP-1, MMPs, TIMPS42,43 and chemokines. The downstream chemoattractive effect caused by exposure of LPCs to increased levels of taurocholate appears likely to recruit HSCs into the LPC niche and places these two cell types within close proximity and potentially in direct contact. Supporting this, activated HSCs have been observed adjacent to LPCs in various mouse model of fibrosis33,41,44 as well as in human liver diseases13,45, demonstrating recruitment of each cell type towards the other during fibrosis. Various studies
have also suggested that membrane contact (and cross-talk) between LPCs and HSCs is a key mediator of fibrogenesis. In this context, our previous work showed that HSCs treated with the TNF superfamily member, lymphotoxin-β, induces NFκB signalling, upregulating chemotaxis-associated factors such as RANTES and ICAM-1, aiding in LPC and inflammatory cell recruitment. As HSCs express the lymphotoxin-β receptor on their cell surface and lymphotoxin-β is a membrane-bound ligand on LPCs, this suggests that direct cell-cell contact between LPCs and HSCs may be required to initiate chemokine expression. Adding to the complexity of this system, high concentrations of taurocholate have also been shown to induce inflammatory gene expression in hepatocytes as well as cytokine/chemokine secretion that may also lead to HSC recruitment and activation. The present study suggests that the DR precedes fibrosis. However, there is an alternate hypothesis stating that fibrosis precedes the DR and there is some evidence to support this in animal studies. It is also possible that the two processes may be injury context-specific thus further investigations are warranted to fully elucidate the temporal nature of LPC niche development. In addition to HSCs, portal fibroblasts may also contribute to CFLD. However, while previous studies have shown that both activated HSCs and myofibroblasts produce collagen in this disease, the role of myofibroblasts derived from portal fibroblasts and indeed the potential recruitment by, and interaction between, these cells and LPCs has not been previously investigated.

In conclusion, this study has shown that the DR is present in CFLD and is correlated with biliary taurocholate levels as well as increasing hepatic fibrosis severity. Thus, we propose that the following model may in part help to explain the pathogenesis of CFLD (Figure 14). In this model, the CFTR defect causes thickened mucous secretions and obstruction of the intrahepatic bile ducts. This obstruction elevates biliary levels of bile salts such as
taurocholate in the vicinity of LPCs, induced as a result of hepatic injury and potentially compromised hepatocyte replication associated with the chronic nature of liver injury in CFLD. In response to supraphysiological levels of bile salts, LPCs firstly undergo proliferation followed by differentiation towards cholangiocytes as part of the DR. Also, in response to altered bile salt levels, LPCs secrete chemokines including MCP-1, MIP1α and RANTES, and this likely attracts HSCs and other immune/inflammatory cells to the LPC niche. Cell-cell contact between LPCs and recruited HSCs may result in activation of HSCs and subsequent fibrogenesis, at least in part via interaction between the HSC lymphotxin-β receptor via cognate ligands on LPCs, with further inflammatory niche chemotaxis, as we previously described 41. Increased understanding of the role of hydrophobic bile acids in CFLD and their impact on the LPC niche, cellular cross-talk with HSCs and induction of the DR will provide important new knowledge of clinical relevance, which may aid in the development of targeted therapeutic strategies to reduce fibrosis in CFLD and potentially in other pediatric cholestatic disorders.

ACKNOWLEDGEMENTS:

We would like to thank Clay Winterford, Nigel Waterhouse, Tam Hong Nguyen and Fernando Guimaraes (QIMR Berghofer Medical Research Institute) for technical support and Prof George Yeoh (University of Western Australia) for his kind gift of the PIL-2 murine liver progenitor cell line.
REFERENCES:


FIGURE LEGENDS

**Figure 1. Evidence of the DR in CFLD.** Immunohistochemistry for CK7 expression in the liver of (A) a donor control subject (10x magnification; 200µm scale bar) and (B, C) a child with CFLD. The CFLD patient shows (B) a marked DR (8x magnification; 160µm scale bar), and (C) numerous single CK7+ LPCs adjacent to areas of DR (40x magnification; 60µm scale bar).

**Figure 2. Assessment of the Ductular Reaction in CFLD and other pediatric cholestatic liver diseases.** (A) CK7 expression in three pediatric cholestatic liver diseases: CFLD, cystic fibrosis liver disease; BA, biliary atresia; NH, idiopathic neonatal hepatitis vs. donor control livers. Statistical calculations were performed using an ANOVA with Kruskal-Wallis test where *p<0.05. (B) Correlation between CK7 expression and hepatic fibrosis stage in livers of children with CFLD (Spearman r=0.59, p<0.0001). Statistical calculations were performed using an ANOVA with Kruskal-Wallis test where *p<0.05, and **p<0.01. (C) Correlation between hepatic CK7 expression and biliary taurocholate levels in children with CFLD (n=7; Pearson r²=0.528; one-tailed p=0.0283). All data represent mean ± SEM.

**Figure 3. Taurocholate induces markers of cholangiocyte differentiation in LPCs.** Taurocholate (0-300µM) induced a dose-dependent increase in mRNA expression of cholangiocyte markers (A) Cx43 (ANOVA, p<0.0001) and (B) Ck19 (ANOVA, p<0.0001) in PIL-2 cells (n=4). Dunnett’s multiple comparisons test was performed relative to untreated cells. PIL-2 cells (n=4) treated with 150µM taurocholate for up to 4 days induced a time-dependent increase in the mRNA expression of cholangiocyte markers (C) Cx43 (ANOVA, p<0.0001), (D) Ck19 (ANOVA, p<0.0001), (E) Hgb4 (ANOVA, p=0.029), and (F) Ggt1 (ANOVA, p=0.001), expressed relative to vehicle control at each time point. Sidak’s multiple
comparisons test was used for comparison at individual time points. All data represented as mean ± SEM and p values are indicated as follows: *p<0.05, **p<0.01, ***p<0.001, and ****p<0.0001.

Figure 4. The effect of taurocholate on markers of hepatocyte differentiation in LPCs. PIL-2 cells treated with 150µM taurocholate for up to 4 days resulted in a time-dependent decrease in mRNA expression for the hepatocyte marker (A) Hepatocyte nuclear factor 4α (Hnf4α; ANOVA, p=0.0255), expressed relative to vehicle control at each time point, although there was no apparent effect on (B) Albumin (Alb) expression (n=4). All data represented as mean ± SEM.

Figure 5. LPC proliferation is induced by taurocholate. Taurocholate (150µM) induced a time-dependent increase in cell proliferation (ANOVA, p=0.0003) in PIL-2 cells treated for 0-4 days, as assessed using an MTT assay (n=4). Sidak's multiple comparisons test was performed for treatment comparison at individual time points where **p<0.01. All data represent mean ± SEM.

Figure 6. Taurocholate induces functional characteristics of biliary differentiation in LPCs in vitro at the protein level. PIL-2 cells were treated with 150µM taurocholate for 4 days. (A) Western blot analysis (n=4) revealed an increased expression of CK19 and SOX9 proteins, while HNF4α protein expression was decreased, relative to the β-actin loading control. Increased expression of acetylated α-tubulin protein relative β-actin was also observed. Band quantification from infrared imaging demonstrated that taurocholate induced statistically significant increases in (B) CK19, (C) SOX9 and (E) acetylated α-tubulin, while conversely, (D) HNF4α protein expression was significantly decreased. Data are expressed as
mean ± SEM and statistical significance was assessed using Student’s t-test where *p<0.05 and ***p<0.001.

**Figure 7. Taurocholate induces morphological and biochemical characteristics of functional biliary differentiation in LPCs in vitro.** (A) PIL-2 cells (n=3) grown on coverslips were treated with 150µM taurocholate for three days vs untreated controls and serum starved overnight to enhance cilia production. Cells were examined (100x magnification) for the presence of primary cilia via expression of acetylated α-tubulin (green). Cells were also labelled with the nuclear stain (DAPI). These images show an increase in the number of primary cilia in response to taurocholate, which when individually-stained spots/lines of fluorescence were quantified (B) show a statistically significant 2.4-fold increase using Student’s t-test (n=3) where **p<0.01. Data are expressed as mean ± SEM. (C) Taurocholate (150µM, 1-4 days) induced a time-dependent increase in GGT enzyme activity (represented as nmole of p-nitroanilide/hour/ml) in conditioned media from PIL-2 cells (n=4; ANOVA, p<0.0001). Sidak’s multiple comparisons test was performed for comparison at individual time points where **p<0.01 and ****p<0.0001. All data represent mean ± SEM.

**Figure 8. Effect of taurocholate in an ex vivo liver model.** To demonstrate the potential physiological relevance of our in vitro observation, we used precision-cut liver slices (in triplicate from each of n=3 mice) treated with 150µM taurocholate for 4 days to demonstrate a time-dependent increase in (A) mRNA expression of the cholangiocyte marker Cx43 (ANOVA, p=0.0354), as well as (B) GGT enzyme activity normalised to tissue weight (6 replicates from each of n=3 mice; ANOVA, p=0.0021). All data represent mean ± SEM.
Figure 9. Profiling of hepatic chemokines expressed and secreted by LPCs after taurocholate treatment. (A) Taurocholate induced a significant increase in Mcp-1, Mip1α, and Rantes mRNA expression in PIL-2 cells at 6 hours. Statistical significance for each gene transcript was assessed using Student's t-test where *p<0.05 and ***p<0.001. (B) Taurocholate treatment induced a significant increase in MIP1α and RANTES protein release into the culture medium at 6 hours. MCP-1 and PDGFβ were also increased but this did not reach statistical significance. The effect of taurocholate was lost after 24 hours, except for the effect on PDGFβ (p=0.0153). TGF-β protein release was not affected by taurocholate treatment. All data represented as mean ± SEM and p values are indicated as follows: *p<0.05 and ***p<0.001.

Figure 10. Treatment of LPCs with taurocholate induces HSC chemotaxis. PIL-2 cells were treated with 150µM taurocholate for 6 hours or 24 hours and conditioned medium (CM) from these cells was used in modified Boyden chambers to examine LX-2 chemotaxis after 24 hours. (A) Treatment of LX-2 HSCs with conditioned medium from either 6 or 24 hour taurocholate-treated PIL-2 cells resulted in significant HSC chemotaxis across the Boyden chamber membranes (n>4). (B) Chemotaxis of LX-2 cells induced by conditioned medium from 24 hour taurocholate-treated PIL-2 cells was inhibited by anti-MIP1α antibody. Statistical significance was determined using ANOVA with Sidak's multiple comparisons test performed for specific comparisons. All data represent mean ± SEM and p values are indicated as follows: **p<0.01, ***p<0.001, and ****p<0.0001.

Figure 11. MIP1α induces HSC chemotaxis. LX-2 cells were placed in modified Boyden chambers with physiologically relevant concentrations of either (A) murine recombinant MIP1α or (B) human recombinant MIP1α and assessed for chemotactic potential. MIP1α...
produced a significant dose-dependent increase in HSC chemotaxis (ANOVA, p=0.022 and p=0.0009, respectively; n=3). Sidak's multiple comparisons test was performed for treatment comparison where *p<0.05. (C) The chemoattractive effect of murine recombinant MIP1α was attenuated by pre-treating LX-2 cells with an anti-CCR5 neutralizing antibody (n=4). (D) Pre-treatment of LX-2 cells with anti-CCR5 also attenuated chemotaxis in response to conditioned medium from 24 h taurocholate-treated PIL-2 cells (n=4). ANOVA with Sidak's multiple comparisons test was performed for specific comparisons where **p<0.01 and ****p<0.0001. All data are expressed as mean ± SEM.

**Figure 12.** Cellular localization of MCP-1 and RANTES expression in liver from children with CFLD. Dual immunofluorescence was performed on CFLD patients to demonstrate the colocalization of CK7+ DR cells with (A) MCP-1 protein expression (63x magnification; 20µm scale bar) and (B) RANTES protein expression (40x magnification; 50µm scale bar). Sections are shown with DAPI (4',6-diamidino-2-phenylindole) in blue, CK7 in red, and either MCP-1 or RANTES in green, with colocalization (merge).

**Figure 13.** Cellular localization of MIP1α expression in liver from children with CFLD. Dual immunofluorescence was performed on CFLD patients for the association of MIP1α protein expression with (A) clusters of CK7+ DR cells (40x magnification; 1.4 zoom; 20µm scale bar) and (B) individual CK7+ LPCs (63x magnification; 20µm scale bar). Sections are shown with DAPI (4',6-diamidino-2-phenylindole) in blue, CK7 in red, and M1Pα in green with colocalization (merge).

**Figure 14.** Proposed model for taurocholate-induced DR and fibrosis in children with CFLD. The cystic fibrosis transmembrane conductance regulator (CFTR) defect results
in obstruction of the intrahepatic bile ducts (red cross). This obstruction elevates biliary taurocholate levels, which drives LPC proliferation and biliary/cholangiocyte differentiation as part of the DR. In response to increased taurocholate, LPCs secrete chemokines that attract HSCs/myofibroblasts (and likely other immune/inflammatory cells) to the LPC niche and/or the region of DR development. Cell-cell contact between LPCs and recruited HSCs may result in activation of HSCs and subsequent fibrogenesis.
Table 1: List of qPCR Primers: [https://www.ncbi.nlm.nih.gov/nuccore/](https://www.ncbi.nlm.nih.gov/nuccore/)

<table>
<thead>
<tr>
<th>Primers</th>
<th>NCBI accession</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tgf-β1</td>
<td>NM_021578</td>
<td>5’-GCTTCAGCTCCACAGAGAAGA-3’</td>
<td>5’-CCAGGCTCCAAATGTAGGGG-3’</td>
</tr>
<tr>
<td>Cx43</td>
<td>NM_010288</td>
<td>5’-AGCTAGGCAGCAGAAAGTAGG-3’</td>
<td>5’-ACTCACTCAGTATAACAAGAACCAT-3’</td>
</tr>
<tr>
<td>Ck19</td>
<td>NM_008471</td>
<td>5’-GTCGAGGGAGGGTTAGAGT-3’</td>
<td>5’-CCATCTGAGCTACCAGCGGAG-3’</td>
</tr>
<tr>
<td>Ggt1</td>
<td>NM_008116</td>
<td>5’-CAGCACCACAGGAAAGTTTGAG-3’</td>
<td>5’-ACGGATTTCACCAGGGACAG-3’</td>
</tr>
<tr>
<td>Itgb4</td>
<td>NM_001005608</td>
<td>5’-GACCTATGAAGAAGGTGCT-3’</td>
<td>5’-GGCTCAGATGCGTCCATAG-3’</td>
</tr>
<tr>
<td>Sox9</td>
<td>NM_011448</td>
<td>5’-AGTACCAGCATCTGCAAAAC-3’</td>
<td>5’-TACCGGTAATCGGGGTGTTCT-3’</td>
</tr>
<tr>
<td>EpCam</td>
<td>NM_008532</td>
<td>5’-CTGGGAGGGGATAAAGC-3’</td>
<td>5’-AGAAGAATGGAACAGGGAC-3’</td>
</tr>
<tr>
<td>Hprt1</td>
<td>NM_013556</td>
<td>5’-CAAATTTTGTTCCTCTCTG-3’</td>
<td>5’-TCTGGCCCTGTATCACAACCACCT-3’</td>
</tr>
<tr>
<td>Rantes</td>
<td>NM_031116</td>
<td>5’-TGCCCCACGTGAAGGATTTATAA-3’</td>
<td>5’-TGCGGGCTCCTCTGGACCAA-3’</td>
</tr>
<tr>
<td>Pdgfb</td>
<td>NM_011057</td>
<td>5’-ATCCGCTCTCTTGATGATCT-3’</td>
<td>5’-GAGGCTTCCAACCTGGACTCC-3’</td>
</tr>
<tr>
<td>Mip1α</td>
<td>NM_011337</td>
<td>5’-CTGCCCTTGTCTCTCTTCT-3’</td>
<td>5’-CTTGGACCCAGCTCTTGTTG-3’</td>
</tr>
<tr>
<td>Mcp-1</td>
<td>NM_011333</td>
<td>5’-GCTGACCCCAAAGGAAGTAGG-3’</td>
<td>5’-GTGCTTGAGGTGTTGTGGGA-3’</td>
</tr>
<tr>
<td>hCcr1</td>
<td>NM_001295</td>
<td>5’-CCTGTGCTAGAGCTAGGGTA-3’</td>
<td>5’-TTGGAAAGTATAAGCCTGGCAT-3’</td>
</tr>
<tr>
<td>hCcr5</td>
<td>NM_000579</td>
<td>5’-TGCTACTCGGGAATCTAAACT-3’</td>
<td>5’-TTCTGAACTTCTCCCGGAAATA-3’</td>
</tr>
<tr>
<td>Hnf4α</td>
<td>NM_008261</td>
<td>Qiagen QuantiTect cat.no. QT00144739</td>
<td></td>
</tr>
<tr>
<td>Alb</td>
<td>NM_009654</td>
<td>Qiagen QuantiTect cat.no. QT00115570</td>
<td></td>
</tr>
</tbody>
</table>
A

% Pixel positive CK7 staining

Control
CFLD
BA
NH
n=4
n=60
n=3
n=5

B

% Pixel positive CK7 staining

Control
Scheuer fibrosis score
n=4
n=18
n=13
n=2
n=11
n=11
n=4

Spearman r=0.59
p<0.0001

C

Biliary Taurocholate (µM)

p=0.0321
r²=0.528

% pixel positive CK7 staining

0.00
0.05
0.10
A

**Hnf4α**

- Control
- Taurocholate

![Graph showing mRNA expression fold change relative to timepoint control](image)

B

**Alb**

- Control
- Taurocholate

![Graph showing mRNA expression fold change relative to timepoint control](image)
A

**CX43**

![Bar chart](chart.png)

Relative mRNA expression fold change

- **Control**
- **Taurocholate**

<table>
<thead>
<tr>
<th>Treatment time (days)</th>
<th>Control</th>
<th>Taurocholate</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>1.0</td>
<td>2.5</td>
</tr>
<tr>
<td>4</td>
<td>1.0</td>
<td>2.0</td>
</tr>
</tbody>
</table>

B

**GGT enzyme activity**

(moles/ hour/ ml)

fold change

- **Control**
- **Taurocholate**

<table>
<thead>
<tr>
<th>Treatment time (days)</th>
<th>Control</th>
<th>Taurocholate</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>1.0</td>
<td>2.0</td>
</tr>
<tr>
<td>4</td>
<td>1.0</td>
<td>1.5</td>
</tr>
</tbody>
</table>
A

![Graph A]

B

![Graph B]

C

![Graph C]

D

![Graph D]
Bile duct obstruction

- New reactive bile ductules
- Biliary differentiation
- Proliferation

↑ Taurocholate

Chemokine secretion (eg. MIP1α)

Chemotaxis

Fibrosis?

Cholangiocytes

Liver progenitor cells

Hepatocytes

Hepatic stellate cells / myofibroblasts
Supplementary Figure Legends

**Supplementary Figure 1.** GGT enzyme activity in conditioned medium from PIL-2 cells treated ± 150 µM taurocholate (Figure 5D), normalized to protein concentration at the conclusion of the experiment (day 4). Data are expressed as mean ± SEM and statistical significance was assessed using Student's t-test where ***p<0.001.

**Supplementary Figure 2.** Expression levels of Ccr1 and Ccr5. LX-2 cells were examined for Ccr1 and Ccr5 mRNA expression relative to the abundant housekeeping gene Hprt1. Data are expressed as mean ± SEM and statistical significance was assessed using Student's t-test where ****p<0.0001.